placebo + eprosartan

placebo + eprosartan refers to a specific comparator arm used in clinical trials, such as the Phase 3 study NCT01631227, to evaluate the efficacy and safety of new formulations of eprosartan. In this double-dummy trial design, patients in the comparator arm receive a placebo tablet (matched to the experimental formulation) administered alongside the marketed active drug, eprosartan mesylate (brand name Teveten). Eprosartan is a non-peptide angiotensin II receptor blocker (ARB) that selectively antagonizes the angiotensin II type 1 (AT1) receptor. By blocking the binding of angiotensin II to AT1 receptors in vascular smooth muscle and the adrenal gland, eprosartan inhibits vasoconstriction and aldosterone secretion, thereby reducing peripheral vascular resistance and lowering blood pressure. It is primarily indicated for the treatment of essential hypertension.

Other names

eprosartan mesylate + placebo